InterCure has signed a binding term sheet for a private placement initially raising NIS 22 million, with potential total proceeds of up to NIS 54 million if all warrants are exercised. The financing is backed by existing and new investors, including CEO Alexander Rabinovich and Bennu Pharma Fund. InterCure will issue approximately 7.9 million ordinary shares at NIS 2.75 per share, and investors will receive warrants to purchase up to an additional 7.9 million shares at NIS 4.125 per share, a roughly 53% premium to the reference closing price. The warrants remain exercisable for five years from issuance.
InterCure Ltd.Company secures up to NIS 54 million in private placement financing, including CEO participation.
Bennu Pharma Fund is participating as an investor in the private placement.